The COlchicine HypERtENsion Trial

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study to investigate the effects of colchicine on measures of vascular and cardiac function in patients with hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Herlev and Gentofte Hospital
• Collaborator: University of Copenhagen
• Treatments: Colchicine

Criteria

Inclusion Criteria:

1. Living address in the Capital Region of Denmark

2. Age >18 years

3. Diagnosed with hypertension

4. Treatment with 1 or more antihypertensive medications

5. Must fulfill at least one of the following high-risk criteria:

1. Diagnosed with type 2 diabetes mellitus OR

2. Treatment with lipid-lowering medication for dyslipidemia OR

3. Treatment with 2 or more antihypertensive medications

6. Female patients should either not be of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing one of the following methods of contraception throughout the study and for 30 days after study completion: Hormonal contraception (oral contraceptives, contraceptive implant, injectable birth control, contraceptive patch, or vaginal ring) or intrauterine device

7. Patients will have given written, informed consent and are able and willing to comply with the requirements of the study protocol

Exclusion Criteria:

1. Colchicine treatment for another cause, e.g. gout

2. Allergy/hypersensitivity to colchicine

3. Known or suspected secondary hypertension, e.g. renal artery stenosis

4. Uncontrolled hypertension (systolic BP >180 mmHg or diastolic BP >110 mmHg)

5. Known other cardiovascular disease (judged by the investigator), e.g. ischemic heart disease, heart failure, significant valvular disease, arrhythmia, stroke, or peripheral artery disease

6. History of malignancy of any organ system excluding a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma, localized prostate cancer and/or localized carcinoma in situ of the cervix

7. Cirrhosis, chronic active hepatitis or other severe hepatic disease

8. Hemodialysis

9. Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2

10. Systemic treatment with moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors or P-glycoprotein inhibitors

11. Anemia, thrombocytopenia or leucopenia defined as any of the following measurements within the last 3 months:

1. Hemoglobin < 7 mmol/L

2. Platelet count < 110 x 10^9/L

3. White blood cell count < 3.0 x 10^9/L

12. Female patients who are pregnant, lactating, or considering becoming pregnant during the study or for 6 months after study completion

13. Significant drug or alcohol abuse during the last year

14. Current use of or plans to initiate chronic systemic steroid therapy during the study (topical or inhaled steroids are allowed)

15. Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea

16. Use of other investigational drugs within 30 days of the time of enrollment

17. Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.